| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PAVmed Inc.$4.67
-0.01 (-0.22%)
F 2Pipeline Score MedTech · Pre-Clinical
Market Cap
45.75 M
EPS
-37.67
P/E Ratio
-
Value Trade
27.93 K
SEC Financials
Q1 2026Dilution Risk
Revenue
22.00 K
R&D Expenses
1.39 M
Operating CF
-2.62 M
Total Assets
45.42 M
Total Liabilities
20.43 M
Equity
39.52 M
D/E Ratio
12,345
0 %
Week
-31.58 %
1 Month
-29.7 %
3 Month
-39.14 %
6 Month
-99.69 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
6.46 M
Monthly Burn
873.00 K
Runway
6.3 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
3.64 K
52 Week Range
6 - 28.44
% held by Insiders
53.78 %
% held by Institutions
14.14 %
Enterprise Value
45.52 M
Total Shares
7.28 M
Short %
0.23 %
Float Shares
3.63 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 870 of 905)
Percentile RankPAVmed Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PAVM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PAVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PAVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PAVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PAVM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PAVM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PAVMPAVmed Provides Business Update and Reports First Quarter 2026 Financial Results Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnos
PAVmed Inc. provided a business update and reported its financial results for Q1 2026. The company is making strides in expanding its commercial opportunities, particularly with Veris Health's implantable physiological monitor nearing FDA submission. Lucid Diagnostics experienced revenue growth from the EsoGuard test and strengthened its financial position. However, PAVmed also reported a notable net loss of $7.0 million along with increased operating expenses in the first quarter.
Read more →PAVMPAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
PAVmed Inc. will host a business update conference call and webcast on May 15, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations and first quarter 2026 financial results. The event will be accessible via the company's website and by telephone.
Read more →PAVMPAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health adva
PAVmed Inc. reported its fourth quarter and full year 2025 financial results, highlighting strengthened capital structure and relaunch of its medical device portfolio. The company is advancing partnerships, including with The Ohio State University for its Veris division, which is progressing towards FDA submission. A positive financial outlook is seen with the expansion of EsoGuard's access, notably through a contract with the U.S. Department of Veterans Affairs. Overall, PAVmed is well-positioned for growth after addressing legacy financial challenges.
Read more →PAVMPAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
PAVmed Inc. has announced a business update conference call and webcast scheduled for March 30, 2026. The call will feature CEO Lishan Aklog discussing the company's operations and growth strategy, alongside CFO Dennis McGrath presenting the fourth quarter 2025 financial results. The event reflects PAVmed's commitment to transparency and engagement with its stakeholders.
Read more →PAVMPAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrant
PAVmed Inc. has announced the successful closing of preferred stock and senior secured note financings, resulting in the elimination of its previously outstanding convertible securities. This transaction raised $30 million from a Series D Preferred Stock offering and an additional $15 million through a senior secured note, significantly enhancing the company's balance sheet. The company plans to seek stockholder approval for the conversion of the Series D Preferred Stock into common stock at a special meeting by April 30, 2026. This strategic move aims to transform PAVmed's capital structure into a more streamlined composition of common stock and long-term debt.
Read more →PAVMPAVmed Announces Reverse Stock Split
PAVmed Inc. has announced a 1-for-30 reverse stock split of its common stock, effective January 2, 2026. This move aims to comply with Nasdaq's minimum bid price requirement. The approved split was confirmed by the company's shareholders during a special meeting in December 2025. As a result of this action, authorized shares will decrease significantly, impacting various equity incentives and outstanding convertible securities.
Read more →PAVMPAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed sign
PAVmed Inc. reported its third quarter 2025 financial results while providing a business update on its subsidiaries. Noteworthy developments include the launch of the commercial phase of a strategic partnership with Veris Health, which aims to bring its implantable physiological monitor to market, and advancements in Medicare coverage for Lucid Diagnostics' EsoGuard test. The company also signed a letter of intent to license advanced endoscopic imaging technology. However, PAVmed continues to face significant operating losses despite recent improvements in its balance sheet.
Read more →PAVMPAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results Lucid processed 2,756 EsoGuard 2Q25 tests, recognized revenue of $1.2 million, and secured CAC meeting on Medicare LCD for EsoGuard to be
PAVmed Inc. has provided a business update alongside the financial results for the second quarter of 2025. The company recognized revenue of $1.2 million from its EsoGuard tests and announced a meeting with CAC regarding Medicare LCD for EsoGuard scheduled for September 4. Despite positive developments, such as completed financings for its subsidiaries and advancements in product development, PAVmed also reported significant losses and high operating expenses, reflecting ongoing financial challenges. The company's leadership expressed optimism about meeting near-term milestones and exploring new business opportunities.
Read more →PAVMPAVmed Provides Business Update and Reports First Quarter 2025 Financial Results Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash V
PAVmed Inc. provided a business update and financial results for the first quarter of 2025, highlighting a capital acquisition that extends its runway beyond key reimbursement milestones. The company ended the quarter with over $40 million in proforma cash. Notably, PAVmed announced a commercial partnership with a major cancer center and resumed the development of an implantable physiological monitor. Despite these advancements, the company reported a net loss of $18.6 million, and revenue significantly declined compared to the prior year.
Read more →PAVMPAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial i
PAVmed Inc. has provided a business update and reported its financial results for the fourth quarter and full year of 2024. The company processed a record volume of diagnostic tests and experienced rapid uptake in concierge medicine contracts, along with securing its first commercial insurance coverage. Key financial improvements include successfully completing debt restructuring and regaining Nasdaq compliance. The company's subsidiaries, Lucid Diagnostics and Veris Health, are positioned to enhance PAVmed's long-term success as they advance their respective commercial strategies.
Read more →PAVMPAVmed Provides Business Update and Third Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage
PAVmed Inc. has provided a business update and reported its financial results for the third quarter of 2024. The company achieved record revenue of $1.2 million for its EsoGuard tests and is preparing to submit clinical evidence for Medicare coverage. Additionally, PAVmed highlighted the completion of a deconsolidation process aimed at regaining Nasdaq compliance, although it faced a substantial net loss this quarter. The company's subsidiaries are actively pursuing growth initiatives and partnerships.
Read more →PAVMPAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors
PAVmed Inc. announced efforts to regain compliance with Nasdaq listing requirements, which include the deconsolidation of Lucid Diagnostics from its financial statements. This change enhances PAVmed's balance sheet by removing Lucid's operating losses from its consolidated financials. The company appointed Sundeep Agrawal, M.D., a seasoned biotech investor, to its board while replacing two departing directors. PAVmed remains committed to exploring alternatives to improve stockholder equity as it requests a hearing from Nasdaq regarding its listing status.
Read more →PAVMPAVmed Provides Business Update and Second Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's M
PAVmed Inc. has released its business update and financial results for the second quarter of 2024, indicating a record volume for EsoGuard tests and an active pursuit of financing. The company aims to strengthen its financial position by making each of its subsidiaries financially independent. Despite revenue growth, PAVmed reported considerable operating losses, which reflects ongoing financial pressure. Lucid Diagnostics is highlighted as a strong asset within the company's portfolio, showing significant commercial progress.
Read more →PAVMPAVmed Provides Business Update and First Quarter 2024 Financial Results Lucid strengthens balance sheet and secures a
PAVmed Inc. provided a business update and financial results for the first quarter of 2024, highlighting substantial growth in revenue from its subsidiary, Lucid Diagnostics. Lucid reported $1.0 million in EsoGuard revenue, marking a 124% increase from the previous year. The company successfully completed a $29.8 million Series B Preferred Stock Offering, which has strengthened its financial position. However, PAVmed recorded a net loss of approximately $22.8 million, raising questions about its operating expenses and overall financial sustainability.
Read more →PAVMPAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Parties to implement a pilot program of
PAVmed Inc. announced that its subsidiary Veris Health has signed a memorandum of understanding with The Ohio State University Comprehensive Cancer Center to implement a pilot program utilizing the Veris Cancer Care Platform. This initiative intends to enhance personalized cancer care through advanced digital health tools, including remote monitoring and telehealth capabilities. PAVmed's executives expressed excitement about working with such a renowned institution, emphasizing the potential benefits for cancer patients receiving systemic therapy. The Veris platform is designed to improve patient outcomes, reduce complications, and aid in overall cancer treatment strategies.
Read more →PAVMMadison Avenue, 25th Floor New York, New York 10017
PAVmed Inc. has announced the approval of a special dividend distribution of approximately 3,331,771 shares of Lucid Diagnostics Inc. to its stockholders. This distribution represents about 6.9% of Lucid Diagnostics' outstanding common stock. Each PAVmed stockholder will receive approximately 0.377 shares of Lucid Diagnostics for every share of PAVmed they hold, with the distribution date set for February 15, 2024. Furthermore, PAVmed will retain a significant 65.2% ownership in Lucid Diagnostics post-distribution.
Read more →PAVMPAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split PAVmed shareholders as of
PAVmed Inc. announced a dividend distribution of around 3.3 million shares of its subsidiary, Lucid Diagnostics, to shareholders on January 15, 2024. This move is part of the repayment of intercompany debt owed to PAVmed by Lucid. Additionally, PAVmed revealed a 1-for-15 reverse stock split effective December 7, 2023, aimed at maintaining compliance with Nasdaq listing requirements. The reverse stock split will also reduce the authorized shares of PAVmed's common stock significantly.
Read more →PAVMPAVmed Provides Business Update and Third Quarter Financial Results Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care
PAVmed Inc. has released a business update alongside its third quarter financial results, noting a remarkable 392% sequential increase in quarterly revenue. This update underscores the significant role of its subsidiary, Lucid Diagnostics, which is achieving increased commercial activity and revenue growth. Additionally, Veris Health is gearing up to launch its upgraded Cancer Care Platform in the fourth quarter. The company remains optimistic about its future prospects, driven by improved commercial execution across its business units.
Read more →PAVMPAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results Conference call and webcast to be held tomorrow, March 15 th at 8:30
PAVmed Inc. has provided an update on its business and preliminary financial results for the fourth quarter and full year of 2022. The company highlighted improvements through a strategic restructuring, focusing resources on immediate commercial activities. Subsidiaries Lucid Diagnostics and Veris Health are also showing positive developments, with Lucid seeing growth in test volumes and Veris gaining traction for its products. A conference call to discuss these updates will take place on March 15, 2023.
Read more →PAVMLucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over t
Lucid Diagnostics recently partnered with the San Antonio Fire Department to execute the first #CheckYourFoodTube Precancer Testing Event, targeting nearly 400 firefighters for esophageal precancer screening. Conducted during Firefighter Cancer Awareness Month, the event successfully implemented noninvasive testing procedures using the EsoGuard Esophageal DNA Test. This initiative aims to enhance cancer prevention and early detection among firefighters, who have been identified as at greater risk for esophageal cancer. Following the event's success, Lucid plans to expand similar testing programs across the country for at-risk individuals.
Read more →PAVMPAVmed and Lucid Diagnostics Provide Strategic Business Update Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercializat
PAVmed Inc. has announced a strategic business update that involves reallocating resources to prioritize the commercialization of Lucid Diagnostics and Veris Health. Measures include a workforce reduction of about 20% and efforts to streamline its product portfolio. The company aims to lower its quarterly cash burn by 25%, reflecting challenges in current market conditions. Consequently, several product developments have been delayed or paused, including EsoGuard and EsoCure devices.
Read more →PAVMPAVmed Provides Business Update and Third Quarter 2022 Financial Results EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held
Provides Business Update and Third Quarter 2022 Financial Results test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch call and webcast to be held today at 4:30 PM EDT YORK, November 15, 2022 (BUSINESS WIRE) -PAVmed Inc. (Nasdaq:
Read more →PAVMPAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results Lucid's EsoGuard test volume grows 60% and LucidDx Labs fully operational Veris Health Cancer Care Platform to commercially launch thi
Provides Business Update and Preliminary Second Quarter 2022 Financial Results EsoGuard test volume grows 60% and LucidDx Labs fully operational Health Cancer Care Platform to commercially launch this year call to be held today at 4:30 PM EDT YORK, August 16, 2022 (BUSINESS W
Read more →PAVMPAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results Conference call to be held today at 4:30
Provides Business Update and Preliminary First Quarter 2022 Financial Results call to be held today at 4:30 PM EDT YORK, May 12, 2022 (BUSINESS WIRE) -PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, oper
Read more →PAVMPAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previou
Read more →PAVMIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE George A. Spritzer , on behalf of himself and all other similarly situated stockholders, Plaintiff, v. LISHAN AKLOG, RONALD M. SPARKS, DAVID S. BATTLEMAN, M.D., JAMES L.
THE COURT OF CHANCERY OF THE STATE OF DELAWARE OF PENDENCY OF CLASS ACTION, SETTLEMENT AND SETTLEMENT HEARING READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF A LAWSUIT AND CONTAINS IMPORTANT INFORMAT
Read more →PAVMLucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination Updated American College of Gastroenterology clinical guideline supports es
Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard on samples collected with Eso
Read more →PAVMPAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results Conference call to be held today at 4:30
Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results call to be held today at 4:30 PM EDT YORK, March 29, 2022 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical techn
Read more →PAVMPAVmed to Hold a Business Update Conference Call on
to Hold a Business Update Conference Call on March 29, 2022 conference call and webcast at 4:30 PM EDT YORK, March 8, 2022 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that
Read more →PAVMPAVmed Appoints Shaun O'Neil as Chief Operating Officer
PAVmed Appoints Shaun O'Neil as Chief Operating NEW YORK, February 24, 2022 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc
Read more →PAVMEvernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors YORK, February 15, 2022 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of can
Read more →PAVMPAVmed and Lucid to Hold Joint Business Update Conference Call on
and Lucid to Hold Joint Business Update Conference Call on November 16, 2021 conference call and webcast at 4:30PM EDT YORK, November 3, 2021 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, a
Read more →PAVMPAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer YORK, October 25, 2021-(BUSINESS WIRE)- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital heal
Read more →PAVMPAVmed Acquires EsophaCap Manufacturer CapNostics
Acquires EsophaCap Manufacturer CapNostics LLC YORK, October 7, 2021 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary
Read more →PAVMPAVmed Acquires EsophaCap Manufacturer CapNostics LLC
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive m
Read more →PAVMPAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results Conference call to be held today at 4:30
Provides Business Update and Preliminary Second Quarter 2021 Financial call to be held today at 4:30 PM EDT YORK, Aug. 12, 2021 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical dev
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers Patients undergoing esophageal precancer testing at centers in Phoenix metro area
Subsidiary Lucid Diagnostics Launches First Lucid Test Centers undergoing esophageal precancer testing at centers in Phoenix metro area YORK, August 10, 2021 (BUSINESSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product,
Read more →PAVMGlobal Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors
Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors YORK, August 03, 2021 (BUSINESSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology compa
Read more →PAVMStanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors
Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board YORK, July 28, 2021 (BUSINESSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, comm
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn
Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn seeking early esophageal precancer detection using Lucid's YORK, July 22, 2021 (
Read more →PAVMTim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors
Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors was eager to initiate a dialogue with Dr. Aklog and the PAVmed team after learning about the company's groundbreaking technologies, unique business mod
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test YORK, June 10, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today
Read more →PAVMPAVmed Launches Digital Health Company Veris Health Inc. New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port
Launches Digital Health Company Veris Health Inc. subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. include first intelligent implantable vascular access port with biologic sensors and wireless communication combined with remote oncology di
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck Esophageal Cell Collection Device
Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck Esophageal Cell Collection Device YORK, May 26, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, an
Read more →PAVMPAVmed Receives European CE Mark Certification for its CarpX Minimally Invasive Carpal Tunnel Device
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX® minimally invasive
Read more →PAVMData Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard c
Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients YORK, May 24,
Read more →PAVMPAVmed Provides Business Update and First Quarter 2021 Financial Results Conference call to be held today at 4:30
Provides Business Update and First Quarter 2021 Financial Results call to be held today at 4:30 PM EDT YORK, May 17, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device c
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021 Dr. David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard
Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021 David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard YORK, May 13, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"),
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization
Subsidiary Lucid Diagnostics Expands Commercial Leadership Team new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization YORK, May 6, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a highly d
Read more →PAVMPAVmed to Hold Business Update Conference Call on May 17, 2021
Company conference call and webcast at 4:30 PM EDT NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will hos
Read more →PAVMDr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors
Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors am delighted to welcome Jacque Sokolov to Lucid's Board of Directors," said Lishan Aklog M.D., Lucid's Executive Chairman and PAVmed's Chairman and Chief Executive Officer. "Jacque brings remarkable br
Read more →PAVMPAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer and Executive Chairman of i
Read more →PAVMPAVmed to Present at the 20th Annual Needham Healthcare Conference
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer
Read more →PAVMPAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
On-demand corporate presentation scheduled for March 17, 2021 NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lis
Read more →PAVMPAVmed Retires Convertible Debt
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company’s outstanding convertible debt, appl
Read more →PAVMPAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world’s
Read more →PAVMPAVmed Announces Closing of its Public Offering of Common Stock
Announces Closing of its Public Offering of Common Stock YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its pre
Read more →PAVMPAVmed Announces Pricing of $45 Million Public Offering of Common Stock
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten public offering (the “O
Read more →PAVMPAVmed Announces Proposed Public Offering of Common Stock
Announces Proposed Public Offering of Common Stock YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it is commencing an und
Read more →PAVMPAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch m
Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal D
Read more →PAVMPAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
Conference call and live webcast was previously scheduled for 4:30 PM EST Lucid Diagnostics strategic advisor and medical diagnostics pioneer Stanley Lapidus to join call NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”),
Read more →PAVMFirst U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed's CarpX Device
U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed's CarpX Device patient presented with symptoms of carpal tunnel syndrome to Dr. Edward J. Armbruster of Mercer-Bucks Orthopaedics, P.C., in greater Philadelphia, who performed minimally inva
Read more →PAVMPAVmed to Hold Business Update Conference Call on February 22, 2021
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, Febr
Read more →PAVMPAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules YORK, Jan. 8, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device comp
Read more →PAVMPAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules YORK, Jan. 6, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company,
Read more →PAVMPAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
Closes Additional $8.1 Million Common Stock Registered Direct Offering YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced the clos
Read more →PAVMPAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today anno
Read more →PAVMPAVmed Announces Registered Direct Offering of its Common Stock
Announces Registered Direct Offering of its Common Stock YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into ag
Read more →PAVMPAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update Conference call to be held today at 4:30 p.m. Eastern time
Reports Third Quarter 2020 Financial Results and Provides Business Update call to be held today at 4:30 p.m. Eastern time YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-st
Read more →PAVMPAVmed to Hold Business Update Conference Call on November 17, 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, Nov
Read more →PAVMPAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Compan
Read more →PAVMPAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update Conference call to be held today at 4:30 p.m. Eastern time
Reports Second Quarter 2020 Financial Results and Provides Business Update call to be held today at 4:30 p.m. Eastern time YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-s
Read more →PAVMPAVmed Secures $7 Million Convertible Note Financing
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has received approximately $7 million in gross proceeds from a private pl
Read more →PAVMPAVmed to Hold Business Update Conference Call on August 18, 2020
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, Aug
Read more →PAVMPAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Shaun O’Neil, Chief Commercial Officer of the Company, will participate
Read more →PAVMPAVmed to Join the Russell 2000 and Russell 3000 Indexes
to Join the Russell 2000 and Russell 3000 Indexes YORK, June 17, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the small-cap Russel
Read more →PAVMFounder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor YORK, June 15, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard Esophageal DNA Test
Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard Esophageal DNA Test YORK, June 11, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today ann
Read more →PAVMPAVmed Collaborates with Canon on DisappEAR Pediatric Ear Tubes Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous
Collaborates with Canon on DisappEAR Pediatric Ear Tubes LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin YORK, June 3, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq:
Read more →PAVMPAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update Conference call to be held today at 4:30 p.m. Eastern time
Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update call to be held today at 4:30 p.m. Eastern time YORK, May 21, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medi
Read more →PAVMPAVmed to Hold Business Update Conference Call on May 21, 2020
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May 21, 2020 at 4:30 p
Read more →PAVMPAVmed Receives FDA 510(k) Clearance for its CarpX Minimally Invasive Carpal Tunnel Device
Receives FDA 510(k) Clearance for its CarpX Minimally Invasive Carpal Tunnel Device YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced it has recei
Read more →PAVMPAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update Conference call to be held today at 4:30 p.m. Eastern time
Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update call to be held today at 4:30 p.m. Eastern time YORK, April 9, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct me
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics' EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
Subsidiary Lucid Diagnostics' EsoCheck Esophageal Cell Collection Device Receives Edison Best New Product Award YORK, April 2, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, t
Read more →PAVMPAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing YORK, March 31, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced it has receive
Read more →PAVMPAVmed to Hold Business Update Conference Call on April 9, 2020
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2019 financial results after the market close on T
Read more →PAVMPAVmed Announces FDA 510(k) Re-submission for its CarpX Minimally Invasive Carpal Tunnel Device Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness end
Announces FDA 510(k) Re-submission for its Minimally Invasive Carpal Tunnel Device data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints YORK, March 9, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (th
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck in Eosinophilic Esophagitis (EoE) Patients Study to assess EsoCheck as a less invasive, more efficient, and cost-effective
Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck in Eosinophilic Esophagitis to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition wh
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett's Esophagus (BE) Progression Biomarkers Using EsoCheck Lucid secures exclusive option to license biomarker tech
Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett's Esophagus (BE) Progression Biomarkers Using EsoCheck secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using
Read more →PAVMPAVmed Adds EsoCure Esophageal Ablation Device with Patented Caldus Technology to Commercial Product Pipeline Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplast
Adds EsoCure Esophageal Ablation Device with Patented Caldus Technology to Commercial Product Pipeline single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett's Esophagus complements Lucid Diagnostics' EsoGuard and EsoCheck
Read more →PAVMU.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device for its EsoGuard Esophageal DNA Test YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today a
Read more →PAVMPAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
Receives Formal Notification of Nasdaq Continued Listing Compliance YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced it has received formal notifi
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer First patients to undergo testing today at gastroenterology center of excellence NEW YORK, Dec. 19, 2019 (GLOBE NE
Read more →PAVMPAVmed Provides Update on CarpX™ Clinical Safety Study
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study. This week, senior PA
Read more →PAVMPAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results fo
Read more →PAVMPAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes and other important biochemical substances through the skin NEW YORK, Nov. 14, 201
Read more →PAVMPAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Compan
Read more →PAVMPAVmed to Hold Business Update Conference Call on November 21, 2019
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the November 14, 2019 dea
Read more →PAVMPAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today anno
Read more →PAVMPAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results fo
Read more →PAVMPAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a hi
Read more →PAVMPAVmed to Hold Business Update Conference Call on September 5, 2019
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the August 14, 2019 deadl
Read more →PAVMPAVmed to Join Russell Microcap Index
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell in
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) mark
Read more →PAVMPAVmed Reports First Quarter 2019 Financial Results and Provides Business Update
Conference call to be held on May 21, 2019 at 4:30 p.m. Eastern time NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the t
Read more →PAVMPAVmed Announces First Human CarpX™ Procedures
First nine patients undergo successful CarpX procedures as part of FIH clinical safety study NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced th
Read more →PAVMPAVmed Announces First Human CarpX Procedures First nine patients undergo successful CarpX procedures as part of FIH clinical safety study
Announces First Human CarpX Procedures nine patients undergo successful CarpX procedures as part of FIH clinical safety study YORK, May 20, 2019 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical devi
Read more →PAVMPAVmed to Hold Business Update Conference Call on May 21, 2019
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report first quarter 2019 financial results on or before May 21, 2019 and
Read more →PAVMPAVmed Reports Excellent DisappEAR Animal Study Results Resorbable pediatric ear tube expected to benefit up to one million U.S. children per year
Reports Excellent DisappEAR Animal Study Results pediatric ear tube expected to benefit up to one million U.S. children per year results of our recently completed 90-day DisappEAR animal study are exciting for two significant reasons," said Lishan Aklog, M.D., PAVmed's Chairma
Read more →PAVMPAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update
Conference call to be held on April 4, 2019 at 4:30 p.m. Eastern time NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for t
Read more →PAVMPAVmed to Hold Business Update Conference Call on April 4, 2019
NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2018 financial results on or before April 4, 2019
Read more →PAVMPAVmed Announces NextFlo Breakthrough Groundbreaking disposable gravity-driven intravenous (IV) infusion set achieves flow accuracy comparable to expensive electronic infusion pumps, independent of IV bag height.
Announces NextFlo Breakthrough disposable gravity-driven intravenous (IV) infusion set achieves flow accuracy comparable to expensive electronic infusion pumps, independent of IV bag height. much of the last century nearly all infusions were driven by gravity. The nurse would
Read more →PAVMPAVmed Announces NextFlo™ Breakthrough
Groundbreaking disposable gravity-driven intravenous (IV) infusion set achieves flow accuracy comparable to expensive electronic infusion pumps, independent of IV bag height. NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed
Read more →PAVMPAVmed Announces PortIO™ Breakthrough
Groundbreaking implantable intraosseous vascular access device achieves unprecedented maintenance-free implant duration of over 60 days in pre-clinical testing NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly di
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advi
Read more →PAVMPAVmed Provides Business Update
NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “I am pleased to report that PAVmed’s 2019 is off to an excellent st
Read more →PAVMPAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission with FDA for EsoCheck™ Cell Collection Device
NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of a 510(k) premarket
Read more →PAVMPAVmed Reports Third Quarter 2018 Financial Results and Provides Business Update
Conference call to be held on November 15, 2018 at 4:30 p.m. Eastern time NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for
Read more →PAVMPAVmed to Hold Business Update Conference Call on November 15, 2018
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report third quarter financial results on or before November 15, 2018 and
Read more →PAVMPAVmed to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
NEW YORK, Oct, Oct. 23, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that Dennis McGrath, PAVmed’s Chief Financial Officer, will present at the Dawson James Se
Read more →PAVMPAVmed Reports Second Quarter 2018 Financial Results and Provides Business Update
Conference call to be held August 22, 2018 at 4:30 p.m. Eastern time NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the
Read more →PAVMPAVmed Inc. to Hold SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATE Conference Call on August 22, 2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report second quarter financial results on or before August 14, 2018 and
Read more →PAVMPAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000 NEW YORK (
Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000 YORK (June 12, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced the closing of its Oversubscribed equity s
Read more →PAVMPAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering NEW YORK (
to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering YORK (June 8, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subs
Read more →PAVMPAVMED TO OFFER OPPORTUNITY TO EXCHANGE OUTSTANDING WARRANTS New Warrants to be Identical to Those Issuable in Recently Announced Rights Offering Exchange Designed to Streamline Capital Structure NEW YORK (
TO OFFER OPPORTUNITY TO EXCHANGE OUTSTANDING WARRANTS Warrants to be Identical to Those Issuable in Recently Announced Rights Offering Designed to Streamline Capital Structure YORK (February 12, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the "Company"), a highly differentiated
Read more →PAVMPAVMED ANNOUNCES CLOSING OF OVER-ALLOTMENT OPTION WITH RESPECT TO FIRM COMMITMENT COMMON STOCK OFFERING NEW YORK (
ANNOUNCES CLOSING OF OVER-ALLOTMENT OPTION WITH RESPECT TO FIRM COMMITMENT COMMON STOCK OFFERING YORK (January 25, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMW) ("PAVmed"), a highly differentiated, multiproduct medical device company, today announced that it has completed the sale
Read more →PAVMPAVMED ANNOUNCES CLOSING OF FIRM COMMITMENT COMMON STOCK OFFERING NEW YORK (
ANNOUNCES CLOSING OF FIRM COMMITMENT COMMON STOCK OFFERING YORK (January 23, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMW) ("PAVmed"), a highly differentiated, multiproduct medical device company, today announced the closing of its previously announced underwritten public offering
Read more →PAVMPAVMED ANNOUNCES FIRM COMMITMENT PUBLIC OFFERING OF COMMON STOCK NEW YORK (
ANNOUNCES FIRM COMMITMENT PUBLIC OFFERING OF COMMON STOCK YORK (January 18, 2018) - PAVmed Inc. (Nasdaq: PAVM, PAVMW)) ("PAVmed"), a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten pu
Read more →PAVMPAVmed Announces Temporary Offer Allowing Warrants to be Exercised at a Reduced Price NEW YORK (
Announces Temporary Offer Allowing Warrants to be Exercised at a Reduced Price YORK (December 28, 2017) - PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the "Company"), a highly differentiated, multiproduct medical device company, today announced that it intends to temporarily reduce the e
Read more →PAVMPAVmed Reports First Quarter 2017 Financial Results and Provides Business Update Conference call to be held
First Quarter 2017 Financial Results and Provides Business Update be held May 31, 2017 at 4:30 p.m. Eastern time 2017) - PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced financial results for the three months ende
Read more →PAVMPAVmed Announces Filing of Exchange Offer Registration Statement with the SEC Exchange Structured to Reward Current Security Holders and Incentivize Long-term Ownership by Both Existing and New Investors NEW YORK (
PAVmed Announces Filing of Exchange Offer Registration Statement with the SEC Exchange Structured to Reward Current Security Holders and Incentivize Long-term Ownership by Both Existing and New Investors NEW YORK (April 10, 2017) - PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly
Read more →PAVMTM NASDAQ: PAVM Lishan Aklog, MD Chairman and CEO APR 2017 2 Disclaimers This presentation contains certain forward - looking statements that involve risks and uncertainties. Actual results and events may differ signific
1 TM NASDAQ: PAVM Lishan Aklog, MD Chairman and CEO APR 2017 2 Disclaimers This presentation contains certain forward - looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward - look
Read more →PAVMPAVmed Announces Closing of Additional Financing Aggregate Private Placement Proceeds Exceed $2.5 Million NEW YORK (
PAVmed Announces Closing of Additional Aggregate Private Placement Proceeds NEW YORK (March 9, 2017) - PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced the closing of approximately $1.0 million in additional fin
Read more →PAVMPAVmed Announces Exchange Offer Exchange to Provide Incentives for Long-Term Ownership by Existing and New Investors New York-(
PAVmed Announces Exchange Offer Exchange to Provide Incentives for Long-Term Ownership by Existing and New Investors New York-(February 23, 2017)-PAVmed Inc. (Nasdaq: PAVM, PAVMW) announced today that the Company intends to effectuate a registered exchange offer (the "Exchang
Read more →PAVMTM NASDAQ: PAVM CORPORATE PRESENTATION Fall 2016 1 Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from r
TM NASDAQ: PAVM CORPORATE PRESENTATION Fall 2016 1 Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements
Read more →PAVMPAVmed Partners with Leading Academic Institutions to Develop Revolutionary Ear Device Agreement provides PAVmed with license to develop and commercialize antibiotic-eluting resorbable ear tube devices expected to benefi
PAVmed Partners with Leading Academic Institutions to Develop Revolutionary Ear Device Agreement provides PAVmed with license to develop and commercialize antibiotic-eluting resorbable ear tube devices expected to benefit up to one million children per New York, NY, (November
Read more →PAVMPAVmed Inc.
PAVmed Inc. Announces Second Quarter 2016 Financial Results and Provides Business Update - Conference Call to be Held August NEW YORK (August 16, 2016) - PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a highly-differentiated multi-product medical device company, tod
Read more →PAVMPAVmed Successfully Completes CarpX
PAVmed Successfully Completes CarpX - Device designed to revolutionize treatment of Carpal Tunnel Syndrome - - Completely percutaneous procedure would replace invasive surgery - New York, NY, June 22, 2016 - PAVmed Inc. (Nasdaq: PAVMU), an innovative multi-product medical d
Read more →PAVMMarcum Microcap Conference June 2, 2016 New York, NY LISHAN
Marcum Microcap Conference June 2, 2016 New York, NY LISHAN AKLOG, MD Chairman & CEO Nasdaq:PAVMU 1 presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discuss
Read more →PAVMPAVMED INC.
PAVMED INC. COMPLETES INITIAL PUBLIC OFFERING - Units to Begin Trading Today on Nasdaq Under the Ticker Symbol "PAVMU"- New York, NY, April 28, 2016 - PAVmed Inc. announced today that it has completed its initial public offering of 1,060,000 units. Each unit consists of one s
Read more →PAVMPAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, April 28, 2016 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq:PAVMU), a multi-product medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and capital efficiency, will visit the Nasdaq MarketSite in Times S
Read more →Competitive Position
How PAVM ranks across every disease it competes inCompetitive Position is a premium feature
See how PAVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial